Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Jacob Gottlieb, Visium Asset Management Boost Exposure to QLT Inc.

Jacob Gottlieb‘s hedge fund, Visium Asset Management, has boosted its position in biotechnology company QLT Inc. (USA) (NASDAQ:QLTI), a new filing with the SEC revealed. Visium currently holds 3.5 million shares of the company, equal to 6.8% of the common stock, and up from 2.0 million revealed in its latest 13F.  The stake is passive by nature, and, at the current share price of QLT, the position’s value amounts to $17.9 million.


The stock of QLT has been down by over 30% since the beginning of the year. For the third quarter of the year, the company posted a loss from continuing operations of $0.15 per share, versus $0.25 in the same period of last year. At the same time, the company reported an almost flat Research & Development expense of $5.2 million. QLT is engaged in production and marketing of ocular products. Also, earlier this year, the company conducted a cash distribution worth $200 million.

Several hedge funds out of those we track have been keeping their long positions in QLT. As follows, Axial Capital, led by Eliav Assouline and Marc Andersen holds 8.9 million shares of the company, worth $41.1 million. Julian Baker And Felix Baker’s Baker Bros. Advisors, and Kevin Kotler’s Broadfin Capital disclosed ownership of 1.5 million shares, and 784,900 shares respectively, with values of $7.1 million, and $3.6 million respectively. All three holdings have remained flat over the quarter.

Jacob Gottlieb and Visium Asset Management caught our attention earlier in October, when they revealed initiating a position in MEI Pharma Inc (NASDAQ:MEIP). The stake amasses over 5% of the company and contains some 932,000 shares.

In the latest 13F, Visium disclosed its largest position in Allergan, Inc. (NYSE:AGN), in which it holds 2.8 million shares, worth $251.6 million. In Cardinal Health, Inc. (NYSE:CAH), the fund holds a $236.2 million stake, which amasses 4.5 million shares. The third-largest is Perrigo Company (NASDAQ:PRGO), in which Visium disclosed ownership of 1.6 million shares, worth $203.3 million.

Disclosure: none

Recommended Reading:

Leon Cooperman Discloses Initial Stake in Atlas Resource Partners

Quadrangle Gp Investors Limits Exposure to Lumos Networks

Oaktree Capital Management Slightly Reduces Position in LSE-listed Stock Spirits Group

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.